Paper1716596
Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis.
Kettel LM and 5 others. Fertil Steril, 1991. Cited by 139 papers, by iCite.
Cite this record
ConductScience Library. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Papers, record 1716596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1716596
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endocrine Glands | Major topic |
| Endometriosis | Major topic |
| Mifepristone | Major topic |
| Pelvic Neoplasms | Major topic |
| Progesterone | Major topic |
| Adolescent | |
| Adrenocorticotropic Hormone | |
| Adult | |
| Amenorrhea | |
| Female | |
| Hormones | |
| Humans | |
| Hydrocortisone | |
| Laparoscopy | |
| Palliative Care | |
| Time Factors |
Source PubMed
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 139 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38854774 | Progesterone resistance in endometriosis: A pathophysiological perspective and potential treatment alternatives. | Reprod Med Biol | 2024 | https://conductscience.org/library/papers/38854774 | PubMed |
| 34405378 | Hormonal treatments for endometriosis: The endocrine background. | Rev Endocr Metab Disord | 2022 | https://conductscience.org/library/papers/34405378 | PubMed |
| 32599565 | 90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies. | J Mol Endocrinol | 2020 | https://conductscience.org/library/papers/32599565 | PubMed |
| 32365199 | Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility. | Endocr Rev | 2020 | https://conductscience.org/library/papers/32365199 | PubMed |
| 32154252 | Mifepristone Treatment in Pregnant Murine Model Induced Mammary Gland Dysplasia and Postpartum Hypogalactia. | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32154252 | PubMed |
| 30407750 | Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies. | ChemMedChem | 2018 | https://conductscience.org/library/papers/30407750 | PubMed |
| 25252652 | Antiprogestins in gynecological diseases. | Reproduction | 2015 | https://conductscience.org/library/papers/25252652 | PubMed |
| 22895965 | Mifepristone for uterine fibroids. | Cochrane Database Syst Rev | 2012 | https://conductscience.org/library/papers/22895965 | PubMed |
| 19609733 | Estradiol and progesterone-induced slowing of gonadotropin-releasing hormone pulse frequency is not reversed by subsequent administration of mifepristone. | Endocrine | 2009 | https://conductscience.org/library/papers/19609733 | PubMed |
| 12222988 | A benefit-risk assessment of medical treatment for uterine leiomyomas. | Drug Saf | 2002 | https://conductscience.org/library/papers/12222988 | PubMed |
| 11333561 | [After levonorgestrel, will mifepristone (RU486) be the next day-after pill?]. | Aten Primaria | 2001 | https://conductscience.org/library/papers/11333561 | PubMed |
| 9250420 | Clinical pharmacokinetics of mifepristone. | Clin Pharmacokinet | 1997 | https://conductscience.org/library/papers/9250420 | PubMed |
| 8297920 | Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. | J Psychiatry Neurosci | 1993 | https://conductscience.org/library/papers/8297920 | PubMed |
| 7969170 | The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. | Mol Cell Biol | 1994 | https://conductscience.org/library/papers/7969170 | PubMed |
| 7962545 | Antioxidant: a new role for RU-486 and related compounds. | J Clin Invest | 1994 | https://conductscience.org/library/papers/7962545 | PubMed |
| 7682909 | Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. | Drugs | 1993 | https://conductscience.org/library/papers/7682909 | PubMed |
| 1615658 | RU 486 (mifepristone). | West J Med | 1992 | https://conductscience.org/library/papers/1615658 | PubMed |
| 1281069 | Mifepristone. Separating fact from fiction. | Drugs | 1992 | https://conductscience.org/library/papers/1281069 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| POMC | 5443 | PubTator's text mining | https://conductscience.org/library/genes/5443 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1716596
GET https://conductscience.org/api/papers/v1/1716596/authors